Preparing independent, creative leaders in the pharmaceutical sciences and in the application of genetics and genomics to the development of safe, effective drugs for patients
The San Francisco Chronicle and the Bay Area News Group, which includes the San Jose Mercury News and Oakland Tribune, have published feature articles this week focused on The Kidney Project, an effort to develop the first implantable bioartificial kidney to treat end-stage renal disease.
Research at the UCSF School of Pharmacy to develop the first implantable bioartificial kidney recently received exceptional private support: $1 million from the family of the late philanthropists Harry and Diana Hind, and $50,000 from the Patterson Barclay Memorial Foundation.
Passengers who travel on American Airlines from September through October 2011 will learn about the surgically implantable bioartificial kidney being developed at UCSF as a permanent solution to end stage renal disease.
Introduction
Budget significance
Reasons for past success
A decade of funding for bioinformatics
New drug discovery directions attract support
Research stalwarts draw funding for decades
New directions in translational research attract support
Expansion of the School’s...
The implantable bioartificial kidney is explained in this December 6, 2010, SmartPlanet video featuring Shuvo Roy, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine.
Shuvo Roy, PhD, an engineer and research scientist, is leading a U.S. project to build the world’s first bioartificial kidney to treat end stage renal disease. The goal is to surgically implant this coffee-cup-sized device in a human patient within 5 to 7 years.
A national research project is under way to develop an surgically implantable bioartificial kidney using the latest advances in science and technology with the goal of both improving the health and lives of patients with end stage renal disease and saving health care dollars.
The model for a surgically implantable bioartificial kidney the size of a coffee cup has been unveiled by the national project's lead researcher, Shuvo Roy, PhD, a member of the UCSF Department of Bioengineering and Therapeutic Sciences.